L-carnitine and contribution to normal lipid metabolism: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006: (Scientific Opinion)

Research output: Contribution to journalJournal articlepeer-review

Standard

L-carnitine and contribution to normal lipid metabolism: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 : (Scientific Opinion). / EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) ; Sjödin, Anders Mikael.

In: E F S A Journal, Vol. 16, No. 1, 5137, 16.01.2018.

Research output: Contribution to journalJournal articlepeer-review

Harvard

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) & Sjödin, AM 2018, 'L-carnitine and contribution to normal lipid metabolism: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006: (Scientific Opinion)', E F S A Journal, vol. 16, no. 1, 5137. https://doi.org/10.2903/j.efsa.2018.5137

APA

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), & Sjödin, A. M. (2018). L-carnitine and contribution to normal lipid metabolism: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006: (Scientific Opinion). E F S A Journal, 16(1), [5137]. https://doi.org/10.2903/j.efsa.2018.5137

Vancouver

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA), Sjödin AM. L-carnitine and contribution to normal lipid metabolism: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006: (Scientific Opinion). E F S A Journal. 2018 Jan 16;16(1). 5137. https://doi.org/10.2903/j.efsa.2018.5137

Author

EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) ; Sjödin, Anders Mikael. / L-carnitine and contribution to normal lipid metabolism: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 : (Scientific Opinion). In: E F S A Journal. 2018 ; Vol. 16, No. 1.

Bibtex

@article{9f89db369f664f6badaf34817211ba54,
title = "L-carnitine and contribution to normal lipid metabolism: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006: (Scientific Opinion)",
abstract = "Following an application from Lonza Ltd., submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Germany, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to L-carnitine and normal lipid metabolism. The food that is proposed as the subject of the health claim is L-carnitine. The Panel considers that L-carnitine is sufficiently characterised. The claimed effect proposed by the applicant is {\textquoteleft}normal lipid metabolism{\textquoteright}. The target population proposed by the applicant is the general population. The Panel considers that contribution to normal lipid metabolism is a beneficial physiological effect. The applicant proposes that the claim submitted with this application is based on the essentiality of a nutrient. The Panel considers that the evidence provided does not establish that dietary L-carnitine is required to maintain normal lipid metabolism in the target population, for which the claim is intended. The Panel concludes that a cause and effect relationship has not been established between the consumption of L-carnitine and contribution to normal lipid metabolism in the target population.",
keywords = "Faculty of Science, L-carnitine, Lipid metabolism, Health claim",
author = "{EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)} and Sj{\"o}din, {Anders Mikael}",
note = "EFSA 2018 5137",
year = "2018",
month = jan,
day = "16",
doi = "10.2903/j.efsa.2018.5137",
language = "English",
volume = "16",
journal = "E F S A Journal",
issn = "1831-4732",
publisher = "European Food Safety Authority (E F S A)",
number = "1",

}

RIS

TY - JOUR

T1 - L-carnitine and contribution to normal lipid metabolism: evaluation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006

T2 - (Scientific Opinion)

AU - EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA)

AU - Sjödin, Anders Mikael

N1 - EFSA 2018 5137

PY - 2018/1/16

Y1 - 2018/1/16

N2 - Following an application from Lonza Ltd., submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Germany, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to L-carnitine and normal lipid metabolism. The food that is proposed as the subject of the health claim is L-carnitine. The Panel considers that L-carnitine is sufficiently characterised. The claimed effect proposed by the applicant is ‘normal lipid metabolism’. The target population proposed by the applicant is the general population. The Panel considers that contribution to normal lipid metabolism is a beneficial physiological effect. The applicant proposes that the claim submitted with this application is based on the essentiality of a nutrient. The Panel considers that the evidence provided does not establish that dietary L-carnitine is required to maintain normal lipid metabolism in the target population, for which the claim is intended. The Panel concludes that a cause and effect relationship has not been established between the consumption of L-carnitine and contribution to normal lipid metabolism in the target population.

AB - Following an application from Lonza Ltd., submitted for authorisation of a health claim pursuant to Article 13(5) of Regulation (EC) No 1924/2006 via the Competent Authority of Germany, the EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA) was asked to deliver an opinion on the scientific substantiation of a health claim related to L-carnitine and normal lipid metabolism. The food that is proposed as the subject of the health claim is L-carnitine. The Panel considers that L-carnitine is sufficiently characterised. The claimed effect proposed by the applicant is ‘normal lipid metabolism’. The target population proposed by the applicant is the general population. The Panel considers that contribution to normal lipid metabolism is a beneficial physiological effect. The applicant proposes that the claim submitted with this application is based on the essentiality of a nutrient. The Panel considers that the evidence provided does not establish that dietary L-carnitine is required to maintain normal lipid metabolism in the target population, for which the claim is intended. The Panel concludes that a cause and effect relationship has not been established between the consumption of L-carnitine and contribution to normal lipid metabolism in the target population.

KW - Faculty of Science

KW - L-carnitine

KW - Lipid metabolism

KW - Health claim

U2 - 10.2903/j.efsa.2018.5137

DO - 10.2903/j.efsa.2018.5137

M3 - Journal article

VL - 16

JO - E F S A Journal

JF - E F S A Journal

SN - 1831-4732

IS - 1

M1 - 5137

ER -

ID: 188485393